Investing.com - Stifel raised its price target on Cullinan Oncology Inc. (NASDAQ:CGEM) to $28 from $22 while maintaining a Buy rating on the stock. The biotech company has delivered an impressive 137% return over the past six months, with shares currently trading at $15.46 and a market capitalization of $906 million.
The firm cited the company's fourth-quarter 2025 update and its position among biotechnology companies advancing programs in B-cell driven autoimmune diseases. Stifel noted that 2026 represents an important year within the autoimmune T-cell engager space. According to InvestingPro data, CGEM holds more cash than debt on its balance sheet, providing financial flexibility as it advances its clinical programs. The platform tracks 12 additional ProTips for investors monitoring the stock.
The firm attributed recent strength in the stock to growing appreciation for the potential role of T-cell engagers in future B-cell treatment paradigms. The analyst pointed to the early March reverse merger of Candid Therapeutics valued at approximately $500 million as an example of this trend.
Cullinan Oncology is scheduled to report initial dose-escalation data for CLN-978 (CD19xCD3) in systemic lupus erythematosus and rheumatoid arthritis in the second quarter of 2026. The company expects to release repeat dose rheumatoid arthritis data in the third quarter of 2026 and preliminary Sjogren's data in the fourth quarter of 2026.
Stifel said internal consistency across datasets with clear pharmacodynamic and biomarker effects, supportive clinical signals, and clean safety profiles without Grade 3 or higher cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome would represent a positive outcome for the therapeutic hypothesis.
In other recent news, Cullinan Oncology has been in the spotlight with several significant developments. The company announced plans for multiple data readouts for its autoimmune and oncology programs, projecting these for 2026. Among the key programs, data from studies on rheumatoid arthritis and systemic lupus erythematosus are expected in the second quarter, with additional data for rheumatoid arthritis in the third quarter and Sjögren's disease trial results anticipated in the fourth quarter. Furthermore, Cullinan reported a preliminary year-end cash position of $439 million, providing insight into its financial standing.
In analyst coverage, Guggenheim initiated coverage on Cullinan Oncology with a Buy rating and a $30 price target, citing the current period as an opportune entry point ahead of important Phase 1 data catalysts expected in 2024. TD Cowen also reiterated a Buy rating after Cullinan’s presentation of CLN-049 acute myeloid leukemia data at the American Society of Hematology conference. Cowen’s discussions with Cullinan’s management highlighted several competitive advantages of the CLN-049 program. These recent developments underscore the ongoing interest and analysis surrounding Cullinan Oncology’s progress in its clinical programs.